Act Capital Management, LLC Inhibikase Therapeutics, Inc. Call Options Transaction History
Act Capital Management, LLC
- $72.5 Million
- Q3 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IKT
# of Institutions
2Shares Held
1.03MCall Options Held
0Put Options Held
0About Inhibikase Therapeutics, Inc.
- Ticker IKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,227,100
- Market Cap $80.7M
- Description
- Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...